The PI3K/Akt Pathway Regulates Oxygen Metabolism Via Pyruvate Dehydrogenase (PDH)-E1α Phosphorylation

Overview

Journal Mol Cancer Ther

Date 2015 May 22

PMID 25995437

Citations 37

Authors

George J Cerniglia

Souvik Dey

Shannon M Gallagher-Colombo

Natalie A Daurio

Stephen Tuttle

Theresa M Busch

Alexander Lin

Ramon Sun

Tatiana V Esipova

Sergei A Vinogradov

Nicholas Denko

Constantinos Koumenis

Amit Maity

Affiliations

Soon will be listed here.

Abstract

Inhibition of the PI3K/Akt pathway decreases hypoxia within SQ20B human head and neck cancer xenografts. We set out to understand the molecular mechanism underlying this observation. We measured oxygen consumption using both a Clark electrode and an extracellular flux analyzer. We made these measurements after various pharmacologic and genetic manipulations. Pharmacologic inhibition of the PI3K/mTOR pathway or genetic inhibition of Akt/PI3K decreased the oxygen consumption rate (OCR) in vitro in SQ20B and other cell lines by 30% to 40%. Pharmacologic inhibition of this pathway increased phosphorylation of the E1α subunit of the pyruvate dehydrogenase (PDH) complex on Ser293, which inhibits activity of this critical gatekeeper of mitochondrial respiration. Expressing wild-type PTEN in a doxycycline-inducible manner in a cell line with mutant PTEN led to an increase in PDH-E1α phosphorylation and a decrease in OCR. Pretreatment of SQ20B cells with dichloroacetate (DCA), which inhibits PDH-E1α phosphorylation by inhibiting dehydrogenase kinases (PDK), reversed the decrease in OCR in response to PI3K/Akt/mTOR inhibition. Likewise, introduction of exogenous PDH-E1α that contains serine to alanine mutations, which can no longer be regulated by phosphorylation, also blunted the decrease in OCR seen with PI3K/mTOR inhibition. Our findings highlight an association between the PI3K/mTOR pathway and tumor cell oxygen consumption that is regulated in part by PDH phosphorylation. These results have important implications for understanding the effects of PI3K pathway activation in tumor metabolism and also in designing cancer therapy trials that use inhibitors of this pathway.

Citing Articles

PTEN loss drives p53 LOH and immune evasion in a novel urothelial organoid model harboring p53 missense mutations.

Hamada A, Kita Y, Sakatani T, Nakamura K, Takada H, Ikeuchi R Oncogene. 2025; .

PMID: 39987272 DOI: 10.1038/s41388-025-03311-5.

Dynamics of the mammalian pyruvate dehydrogenase complex revealed by in-situ structural analysis.

Wang C, Ma C, Xu Y, Chang S, Wu H, Yan C Nat Commun. 2025; 16(1):917.

PMID: 39843418 PMC: 11754459. DOI: 10.1038/s41467-025-56171-8.

Glutaminase-2 Expression Induces Metabolic Changes and Regulates Pyruvate Dehydrogenase Activity in Glioblastoma Cells.

De Los Santos-Jimenez J, Campos-Sandoval J, Rosales T, Ko B, Alonso F, Marquez J Int J Mol Sci. 2025; 26(1.

PMID: 39796278 PMC: 11721818. DOI: 10.3390/ijms26010427.

CAVPENET Peptide Inhibits Prostate Cancer Cells Proliferation and Migration through PP1γ-Dependent Inhibition of AKT Signaling.

Matos B, S Gomes A, Bernardino R, Alves M, Howl J, Jeronimo C Pharmaceutics. 2024; 16(9).

PMID: 39339236 PMC: 11434739. DOI: 10.3390/pharmaceutics16091199.

The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer.

Fontana F, Giannitti G, Marchesi S, Limonta P Int J Biol Sci. 2024; 20(8):3113-3125.

PMID: 38904014 PMC: 11186371. DOI: 10.7150/ijbs.89942.

References

Cerniglia G, Pore N, Tsai J, Schultz S, Mick R, Choe R . Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One. 2009; 4(8):e6539. PMC: 2716529. DOI: 10.1371/journal.pone.0006539. View

Rodon J, Dienstmann R, Serra V, Tabernero J . Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013; 10(3):143-53. DOI: 10.1038/nrclinonc.2013.10. View

Cosse J, Ronvaux M, Ninane N, Raes M, Michiels C . Hypoxia-induced decrease in p53 protein level and increase in c-jun DNA binding activity results in cancer cell resistance to etoposide. Neoplasia. 2009; 11(10):976-86. PMC: 2745664. DOI: 10.1593/neo.09632. View

Ramanathan A, Schreiber S . Direct control of mitochondrial function by mTOR. Proc Natl Acad Sci U S A. 2010; 106(52):22229-32. PMC: 2796909. DOI: 10.1073/pnas.0912074106. View

Wong K, Engelman J, Cantley L . Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev. 2009; 20(1):87-90. PMC: 2822054. DOI: 10.1016/j.gde.2009.11.002. View

Courtney K, Corcoran R, Engelman J . The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010; 28(6):1075-83. PMC: 2834432. DOI: 10.1200/JCO.2009.25.3641. View

Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K . MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010; 9(7):1956-67. DOI: 10.1158/1535-7163.MCT-09-1012. View

Carmeliet P, Jain R . Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011; 10(6):417-27. DOI: 10.1038/nrd3455. View

Overgaard J . Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis. Radiother Oncol. 2011; 100(1):22-32. DOI: 10.1016/j.radonc.2011.03.004. View

10.

Chang K, Tsai S, Wu C, Yen C, Chuang B, Chang J . Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res. 2011; 17(22):7116-26. DOI: 10.1158/1078-0432.CCR-11-0796. View

11.

Wallin J, Edgar K, Guan J, Berry M, Prior W, Lee L . GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther. 2011; 10(12):2426-36. DOI: 10.1158/1535-7163.MCT-11-0446. View

12.

Fokas E, Im J, Hill S, Yameen S, Stratford M, Beech J . Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res. 2011; 72(1):239-48. DOI: 10.1158/0008-5472.CAN-11-2263. View

13.

Milosevic M, Warde P, Menard C, Chung P, Toi A, Ishkanian A . Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res. 2012; 18(7):2108-14. DOI: 10.1158/1078-0432.CCR-11-2711. View

14.

Janssens G, Rademakers S, Terhaard C, Doornaert P, Bijl H, van den Ende P . Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol. 2012; 30(15):1777-83. DOI: 10.1200/JCO.2011.35.9315. View

15.

Lin A, Hahn S . Hypoxia imaging markers and applications for radiation treatment planning. Semin Nucl Med. 2012; 42(5):343-52. DOI: 10.1053/j.semnuclmed.2012.04.002. View

16.

Zannella V, Dal Pra A, Muaddi H, McKee T, Stapleton S, Sykes J . Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res. 2013; 19(24):6741-50. DOI: 10.1158/1078-0432.CCR-13-1787. View

17.

Barbi de Moura M, Van Houten B . Bioenergetic analysis of intact mammalian cells using the Seahorse XF24 Extracellular Flux analyzer and a luciferase ATP assay. Methods Mol Biol. 2014; 1105:589-602. DOI: 10.1007/978-1-62703-739-6_40. View

18.

Kelly C, Hussien K, Fokas E, Kannan P, Shipley R, Ashton T . Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia. Radiother Oncol. 2014; 111(1):72-80. PMC: 4070024. DOI: 10.1016/j.radonc.2014.02.007. View

19.

Brizel D, Dodge R, Clough R, Dewhirst M . Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol. 2000; 53(2):113-7. DOI: 10.1016/s0167-8140(99)00102-4. View

20.

Busch T, Hahn S, Evans S, Koch C . Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide ]. Cancer Res. 2000; 60(10):2636-42. View